[Market Focus] Curiox Biosystems Surges Again After Recent Pause

After hitting a record high last month and then plummeting, the stock price of Curiox Biosystems (hereafter Curiox) is once again on the rise. As of 10:30 a.m. on September 11, 2025, on the KOSDAQ market, Curiox shares are trading at 52,000 won, up 16.72% from the previous day's closing price.

Curiox is a company that develops and sells automated cell preprocessing devices, which are essential in new drug development and in vitro diagnostics using cells. The main advantage is that it can produce more uniform results compared to manual preprocessing. Curiox has estimated that the global market size for manual cell analysis using centrifuges is about 19 trillion won. The company has stated that its long-term goal is to secure a 30-50% market share.

Last year, Curiox posted sales of 4.6 billion won and a net loss of 8.1 billion won. In the first half of this year, sales reached 1 billion won, but the net loss soared to 18.3 billion won. Significant revenue has yet to materialize.

At the end of last year, Curiox partnered with global life science equipment company Revity to begin production of the next-generation cell analysis product "Pluto."

Nam-Yong Kim, CEO of Curiox, recently stated in a media interview, "The market response to the 'Pluto Series' has been positive, and we are currently in contract discussions with the world's top four liquid handling automation workstation manufacturers." He added, "Given the status of these contracts, we expect to reach the break-even point (BEP) this year."